Core Challenge: Proof of Concept
Accelerating the path from concept to commercialization. Focused execution on clinical trial operations, achieving verifiable product-market fit, and positioning for capital acquisition.
Core Challenge: Sustainable Growth
Navigating growth and technological integration. Comprehensive whitespace assessment, AI pipeline integration, and rigorous M&A target diligence to ensure long-term market dominance.
Core Challenge: Capital Allocation
De-risking capital allocation. Unbiased investment analysis, deep company diligence, and predictive market modeling to validate healthtech investments before deployment.
Viral Gandhi operates at the intersection of MedTech investment, clinical execution, and strategic narrative. Aviga Health Advisors is built on his 15+ years of cross-functional industry expertise. He holds a Bachelor of Science and a Master of Science in Bioengineering from the University of Pennsylvania and is a former Stanford Biodesign Innovation Fellow.
Currently a Venture Advisor at KCK Medtech, following investment roles at Longitude Capital, OrbiMed, and the external investments team of Edwards Lifesciences (NYSE: EW). As a two-time founder (GlucoLens and Aperture Medical), he possesses direct experience in early-stage company building and capital acquisition.
Viral has directed clinical programs from first-in-human studies through large-scale randomized trials. He served as VP of Clinical at Revamp Medical and led trial operations for the PARTNER trials at Edwards Lifesciences. His advisory and early-stage consulting work includes Auris Health, Imperative Care, Ceribell, and Hawthorne Health.
Prior to his operational and investment roles, Viral led Medtech investigative coverage for the Financial Times Group, publishing over 225 stories and interviewing more than 2,000 industry figures.
Institutional
Experience
